Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1994 Nov;57(Suppl):62–64. doi: 10.1136/jnnp.57.suppl.62

Treatment of multiple sclerosis with IVIg: potential effects and methodology of clinical trials.

P S Sørensen 1
PMCID: PMC1016729  PMID: 7964858

Abstract

There is extensive evidence that immune mechanisms are involved in the pathogenesis of multiple sclerosis (MS). A potential treatment effect of IVIg in MS could be mediated by several mechanisms as IVIg is able to modulate the immune response in different ways. The evidence of the effect of IVIg in MS is at present based on the results of small open trials, some of which have been encouraging. Confirmation of a beneficial effect of IVIg must await the results of placebo-controlled, double-blind trials. A placebo-controlled, crossover study of IVIg is being conducted using magnetic resonance imaging (MRI) for monitoring disease activity. However, the ultimate proof of efficacy must come from studies of parallel groups with large numbers of patients followed for long periods with repeated clinical observations of neurological function, for example, the Expanded Disability Status Scale (EDSS) or the Neurological Rating Scale (NRS).

Full text

PDF
62

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Achiron A., Pras E., Gilad R., Ziv I., Mandel M., Gordon C. R., Noy S., Sarova-Pinhas I., Melamed E. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol. 1992 Dec;49(12):1233–1236. doi: 10.1001/archneur.1992.00530360031013. [DOI] [PubMed] [Google Scholar]
  2. Andersson U. G., Björk L., Skansén-Saphir U., Andersson J. P. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology. 1993 Jun;79(2):211–216. [PMC free article] [PubMed] [Google Scholar]
  3. Bornstein M. B., Miller A., Slagle S., Weitzman M., Drexler E., Keilson M., Spada V., Weiss W., Appel S., Rolak L. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology. 1991 Apr;41(4):533–539. doi: 10.1212/wnl.41.4.533. [DOI] [PubMed] [Google Scholar]
  4. Hafler D. A., Weiner H. L. MS: a CNS and systemic autoimmune disease. Immunol Today. 1989 Mar;10(3):104–107. doi: 10.1016/0167-5699(89)90236-3. [DOI] [PubMed] [Google Scholar]
  5. Isaac C., Li D. K., Genton M., Jardine C., Grochowski E., Palmer M., Kastrukoff L. F., Oger J., Paty D. W. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology. 1988 Oct;38(10):1511–1515. doi: 10.1212/wnl.38.10.1511. [DOI] [PubMed] [Google Scholar]
  6. Jungi T. W., Brcic M., Kuhnert P., Spycher M. O., Li F., Nydegger U. E. Effect of IgG for intravenous use on Fc receptor-mediated phagocytosis by human monocytes. Clin Exp Immunol. 1990 Oct;82(1):163–169. doi: 10.1111/j.1365-2249.1990.tb05421.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Oger J., Kastrukoff L. F., Li D. K., Paty D. W. Multiple sclerosis: in relapsing patients, immune functions vary with disease activity as assessed by MRI. Neurology. 1988 Nov;38(11):1739–1744. doi: 10.1212/wnl.38.11.1739. [DOI] [PubMed] [Google Scholar]
  8. Rothfelder U., Neu I., Pelka R. Therapie der Multiplen Sklerose mit Immunglobulin G. MMW Munch Med Wochenschr. 1982 Jan 29;124(4):74–78. [PubMed] [Google Scholar]
  9. Schuller E., Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol. 1983;22(3):205–212. doi: 10.1159/000115560. [DOI] [PubMed] [Google Scholar]
  10. Selmaj K., Plater-Zyberk C., Rockett K. A., Maini R. N., Alam R., Perkin G. D., Rose F. C. Multiple sclerosis: increased expression of interleukin-2 receptors on lymphocytes. Neurology. 1986 Oct;36(10):1392–1395. doi: 10.1212/wnl.36.10.1392. [DOI] [PubMed] [Google Scholar]
  11. Soukop W., Tschabitscher H. Gammaglobulintherapie bei Multipler Sklerose (MS). Theoretische Uberlegungen und erste klinische Erfahrungen mit 7S-Immunglobulinen in der MS-Therapie. Wien Med Wochenschr. 1986 Sep 30;136(18):477–480. [PubMed] [Google Scholar]
  12. Tenser R. B., Hay K. A., Aberg J. A. Immunoglobulin G immunosuppression of multiple sclerosis. Suppression of all three major lymphocyte subsets. Arch Neurol. 1993 Apr;50(4):417–420. doi: 10.1001/archneur.1993.00540040069017. [DOI] [PubMed] [Google Scholar]
  13. Weiner H. L., Hafler D. A. Immunotherapy of multiple sclerosis. Ann Neurol. 1988 Mar;23(3):211–222. doi: 10.1002/ana.410230302. [DOI] [PubMed] [Google Scholar]
  14. Weiner H. L., Hafler D. A. Immunotherapy of multiple sclerosis. Ann Neurol. 1988 Mar;23(3):211–222. doi: 10.1002/ana.410230302. [DOI] [PubMed] [Google Scholar]
  15. Willoughby E. W., Grochowski E., Li D. K., Oger J., Kastrukoff L. F., Paty D. W. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol. 1989 Jan;25(1):43–49. doi: 10.1002/ana.410250107. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES